Urgent Evaluation of Painless Hematuria

Epidemiology & Risk Factors

• Painless hematuria is the presenting symptom in approximately 80 % of bladder cancer cases and must be investigated even when it appears self‑limited or intermittent. 1
• The absence of pain increases the likelihood of underlying malignancy compared with painful hematuria. 2
• Tobacco smoking accounts for roughly 50 % of bladder cancer cases. 1
• Occupational exposure to aromatic amines or ionizing radiation is an established risk factor for urothelial carcinoma. 1
• Anticoagulant or antiplatelet therapy should not preclude a full hematuria work‑up; hematuria must be evaluated regardless of medication use. 2

Initial Clinical Assessment

• A comprehensive history (smoking, occupational exposures, medication use) and bimanual pelvic examination are recommended as part of the initial assessment. 1
• Baseline laboratory testing—including complete blood count, renal function, and liver function tests—should be obtained to identify anemia, renal impairment, or hepatic disease that may influence management. 1

Urine Cytology

• Urine cytology should be collected at the time of, or before, cystoscopy; it is valuable for detecting high‑grade urothelial carcinoma but is not suitable as a primary diagnostic tool. 1
• Cytology reports should follow the Paris System for standardized interpretation. 3

Cystoscopic Evaluation (Mandatory)

• All adults with gross hematuria require office cystoscopy, even if the hematuria has resolved, to directly visualize the bladder and identify lesions. 2
• Cystoscopy is also indicated for patients with microscopically confirmed hematuria when no benign cause is evident. 2

Upper Tract Imaging

• Imaging of the upper urinary tract is essential to exclude synchronous upper‑tract urothelial carcinoma, which occurs in about 2.5 % of cases. 1
• CT urography is the first‑line imaging modality; alternative options include MRI urography, intravenous pyelogram, retrograde pyelogram, and renal ultrasound with retrograde pyelogram. 1
• Upper‑tract imaging is especially critical in patients with high‑grade bladder cancer to detect concurrent lesions. 3

Tissue Diagnosis & Staging (TURBT)

• When cystoscopy reveals a solid tumor or suggests muscle invasion, a transurethral resection of bladder tumor (TURBT) performed under anesthesia with bimanual examination is recommended. 1
• The goal of TURBT is complete resection of all visible tumor tissue. 1
• Adequate muscle sampling (including lamina propria and detrusor muscle) must be obtained to ensure accurate pathological staging. 1
• Bladder biopsies should be taken from any suspicious areas, and mapping biopsies are advised when cytology is positive or there is a history of high‑grade disease. 1

Metastatic Work‑Up for High‑Risk Patients

• Patients deemed high‑risk for metastatic spread should undergo CT of the chest, abdomen, and pelvis to assess for distant disease. 1

Critical Pitfalls & Contra‑Indications

• Do not dismiss hematuria in patients on anticoagulation; a full urologic evaluation is mandatory. 2
• Urinary cytology and molecular markers (e.g., NMP22, UroVysion) should not be used as initial screening tools in the hematuria work‑up. 2
• Screening asymptomatic individuals with routine urinalysis for cancer detection is not recommended. 2

Diagnostic Workup for Suspected Bladder Cancer

Initial Presentation and Symptoms

• Painless hematuria occurs in approximately 80% of patients with bladder cancer, which warrants investigation in all cases 4, 5, 6
• Irritative voiding symptoms, including dysuria, increased frequency, and urgency, are particularly common in invasive or high-grade tumors 4, 5, 7
• Less commonly, urinary tract infection, upper tract obstruction, or pain in advanced lesions can occur 8, 9
• Bone pain or flank pain can occur in advanced cases 4, 7

Diagnostic Algorithm

Step 1: Initial Evaluation

• Office cystoscopy should be performed to determine if a lesion is present 8, 9
• Urine cytology should be obtained around the time of cystoscopy 8, 9

Step 2: Imaging

• If cystoscopy reveals a solid tumor, or suggests muscle invasion, CT scan or MRI of the abdomen and pelvis should be performed before TURBT 8, 9
• Upper urinary tract imaging is essential and should include one of the following: CT urography, MRI urography, intravenous pyelogram, retrograde pyelogram, or renal ultrasound with retrograde pyelogram 4, 5, 10

Step 3: Definitive Diagnosis

• Transurethral resection of bladder tumor (TURBT) with bimanual examination under anesthesia should be performed 4, 5, 10
• Complete resection of all visible tumor tissue should be attempted, and adequate muscle sampling is critical for accurate staging 4, 5, 6

Step 4: Laboratory Testing

• Complete blood work, including hematology and biochemistry, should be performed 4, 5, 7
• Liver function tests should be performed for patients with high risk of metastases 4, 7

Step 5: Additional Testing for Suspected Advanced Disease

• Metastatic workup, including CT chest, abdomen, and pelvis, should be performed for patients with high risk of metastases 4, 7
• Bone scan should be performed if elevated levels of alkaline phosphatase are detected 8, 9

Important Considerations

• The management of bladder cancer is based on pathological findings, with attention to histology, grade, and depth of invasion 4, 6, 7
• Approximately 75% of patients present with non-muscle-invasive bladder cancer (NMIBC), while the remainder have muscle-invasive disease (MIBC) 4, 7
• Concurrent carcinoma in situ (CIS) is an adverse prognostic factor requiring additional evaluation 4, 6

Common Pitfalls to Avoid

• Inadequate muscle sampling during TURBT can lead to understaging 4, 6
• Failing to perform upper tract imaging can lead to missing synchronous upper tract urothelial cancer 4, 7
• Neglecting to obtain urine cytology can lead to missing malignant cells from anywhere in the urinary tract 8, 9
• Overlooking variant histologies can affect prognosis and treatment decisions 4, 7, 10